Predictors of Survival Among Colorectal Cancer Patients in a Low Incidence Area
Received 2 October 2019
Accepted for publication 4 January 2020
Published 21 January 2020 Volume 2020:12 Pages 451—459
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Harikrishna Nakshatri
Nahla Azzam, 1 Yazed AlRuthia, 2, 3 Othman Alharbi, 1 Abdulrahman Aljebreen, 1 Majid Almadi, 1, 4 Maryam Alarfaj, 5 Khalid Alsaleh, 6 Abdulaziz Almasoud, 1 Muhannad Alsharidah, 1 Sarah Alseneidi, 1 Fatimah Alali, 1 Malak Alalwan 1
1Gastroenterology Division, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 3Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 4Division of Gastroenterology, The McGill University Health Center, Montreal General Hospital, McGill University, Montreal, Canada; 5Department of Pharmaceutical Care, King Saud University Medical City, Riyadh, Saudi Arabia; 6Department of Hematology/Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Correspondence: Yazed AlRuthia
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Background: Colorectal cancer is the third most common malignancy in Saudi Arabia. The best therapeutic regimen for colorectal cancer is a matter of ongoing debate and data on its treatment in Saudi Arabia are limited.
Purpose: The objective of this study was to explore the predictors of survival and to compare the risk of mortality among colorectal cancer patients treated with different therapeutic modalities.
Patients and Methods: The study utilized data from the electronic colorectal cancer registry of a university-affiliated tertiary care hospital. The Kaplan-Meier survival analysis was used to estimate the survival rates over 36 months of follow-up across rectal and colon cancer patients as well as different sociodemographic and medical characteristics. Bivariate and multiple Cox proportional-hazards regressions were conducted to estimate the risk of mortality among rectal and colon cancer patients undergoing different treatments.
Results: The number of patients in the registry who were followed up for 36 months was 143 patients. The majority of patients had colon cancer (74.13%). Rectal cancer patients had generally better survival estimates compared to their colon cancer counterparts. Colon cancer patients treated with chemotherapy had a significantly lower risk of mortality controlling for the use of surgery, radiotherapy, and other variables including age, gender, stage of cancer, and family history of colorectal cancer (HR=0.33; P=0.03). Additionally, colon cancer patients with a family history of colorectal cancer had significantly higher risk of mortality (HR=3.40; P=0.02).
Conclusion: The findings of this study highlight the value of chemotherapy in managing colon cancer patients.
Keywords: colorectal cancer, surgery, chemotherapy, survival, Saudi Arabia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]